# Rein Therapeutics, Inc. (RNTX) · Edgar & Edgarette company card

> Rein Therapeutics (RNTX) reported revenue of $0 million in FY2025, operating margin null against a -3.8% median for pharmaceutical preparations, equity 70.0% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1420565 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/RNTX) · [JSON](https://www.pops4.com/boards/company/RNTX.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $0 |
| Revenue growth, 1 year | — |
| Revenue growth per year | — |
| Operating margin | -Infinity% (prior year -Infinity%) |
| Net margin | -Infinity% |
| Operating cash flow | −$19M |
| Capital spending | — |
| Free cash flow | — |
| Cash | $3M |
| Long-term debt | — |
| Total assets | $24M |
| Total equity | $17M |
| Equity ÷ assets | 70.0% |
| Return on equity | -294.8% |
| Dividend per share | $0 |
| Dividend years rising | 0 |

## Readings, computed from those figures

- Altman Z: -66.28 (distress zone)
- Piotroski F: 2 of 9 (weak)
- Health Harbor boat: Weathered boat · two warning signs · operating cash flow was negative (-$19.4M in FY2025); operating loss: a margin of -Infinity% in FY2025

## Edgarette's reading

Exposure: revenue $0K (FY2025). Experience: one year on record; operating margin null, up from null. Soundness: equity 70.0% of assets, return on equity -294.8%. Credibility: four or more audited years, reasonable weight. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin null against a -3.8% median.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 1, latest 2026-08-27 ([filing](https://www.sec.gov/Archives/edgar/data/1420565/000119312526371260/0001193125-26-371260-index.htm))
- Item 5.02 Director or officer change: 1, latest 2026-02-19 ([filing](https://www.sec.gov/Archives/edgar/data/1420565/000119312526059545/0001193125-26-059545-index.htm))

## Recent filings

- 8-K · filed 2026-09-04 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1420565/000119312526383726/0001193125-26-383726-index.htm)
- 8-K · filed 2026-08-27 · 3.01 Notice of Delisting or Failure to Satisfy a Listing Rule · [filing](https://www.sec.gov/Archives/edgar/data/1420565/000119312526371260/0001193125-26-371260-index.htm)
- 10-Q · filed 2026-08-14 · [filing](https://www.sec.gov/Archives/edgar/data/1420565/000119312526350270/0001193125-26-350270-index.htm)
- 8-K · filed 2026-07-21 · 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/1420565/000119312526310315/0001193125-26-310315-index.htm)
- DEF 14A · filed 2026-06-08 · [filing](https://www.sec.gov/Archives/edgar/data/1420565/000119312526260809/0001193125-26-260809-index.htm)
- 10-Q · filed 2026-05-15 · [filing](https://www.sec.gov/Archives/edgar/data/1420565/000119312526225352/0001193125-26-225352-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001420565.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1420565

## Cite

POPS4, Edgar & Edgarette: Rein Therapeutics, Inc. (RNTX) company card, from the company's own SEC filings, accessed 2026-11-05, https://www.pops4.com/boards/company/RNTX. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.